This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zile, M. R. Search for Related Content PubMed PubMed Citation Articles by Zile, M. R. Pubmed/NCBI databases Medline Plus Health Information Heart Failure Statins Related Collections Congestive

(Circulation. 2005;112:300-303.)
© 2005 American Heart Association, Inc.

Editorial

Treating Diastolic Heart Failure With Statins

"Phat"^* Chance for Pleiotropic Benefits

Michael R. Zile, MD

From the Division of Cardiology, Department of Medicine, Medical University of South Carolina and RHJ Department of Veterans Affairs Medical Center, Charleston, SC.

Reprint requests to Michael R. Zile, MD, Division of Cardiology, Dept of Medicine, Medical University of South Carolina, 135 Rutledge Ave, Suite 1201, PO Box 250592, Charleston, SC 29425. E-mail zilem@musc.edu

Key Words: Editorials • heart failure • statins • lipids

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Diastolic heart failure (DHF) is a significant healthcare problem.^1,2 Nearly 50% of all patients with chronic heart failure have DHF. Once hospitalized for heart failure, patients with DHF have a 50% chance of rehospitalization within 6 months. Patients with DHF have a 5% to 6% yearly mortality rate. It is estimated that treating patients with DHF costs in excess of $3.5 billion/year. Despite the significant impact that DHF has on heart failure incidence, prognosis, and cost, only 1 large randomized clinical trial has been completed that examined the treatment of patients with DHF, Candesartan cilexitil (Atacand) in Heart failure Assessment of Reduction Mortality and morbidity-Preserved (CHARM-Preserved).³

See p 357

The poor clinical outcomes and the limited treatment options for patients with DHF underscore the importance and uniqueness of the Fukuta et al study published in this issue of Circulation.⁴ In this study, the authors conclude that treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may lower both mortality and morbidity rates in patients with DHF. Enthusiasm for and clinical application of the results of this study must be tempered by the fact that this represents a "preliminary report"; however, if proven effective in large randomized clinical trials, this therapeutic approach will represent an innovation and potentially a paradigm shift in the treatment of patients with DHF.

This editorial will focus on addressing 4 questions: (1) Does hyperlipidemia contribute to the pathophysiology of DHF?; (2) Why would these authors believe that statin therapy would reduce morbidity and mortality in patients . . . [Full Text of this Article]

This article has been cited by other articles:

				S. J. Lester, A. J. Tajik, R. A. Nishimura, J. K. Oh, B. K. Khandheria, and J. B. Seward Unlocking the Mysteries of Diastolic Function Deciphering the Rosetta Stone 10 Years Later. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 679 - 689. [Abstract] [Full Text] [PDF]